German vaccine maker CureVac and the European Union (EU) are close to finalizing a supply deal for the company’s COVID-19 vaccine candidate that will stock the EU with hundreds of millions of doses.

CureVac said that it is now in “advanced discussions” with the European Commission and anticipates signing a contract for 225 million doses of the mRNA-based vaccine for European member states.

The planned contract, which will be paid for from the EU’s $2.7 billion COVID-19 vaccine fund, includes an option to buy an additional 180 million doses.